General American Investors Co. Inc. Purchases 130,877 Shares of Maravai LifeSciences Holdings, Inc. $MRVI

General American Investors Co. Inc. grew its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 8.3% during the first quarter, HoldingsChannel reports. The institutional investor owned 1,716,193 shares of the company’s stock after purchasing an additional 130,877 shares during the period. General American Investors Co. Inc.’s holdings in Maravai LifeSciences were worth $4,857,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of MRVI. Virtu Financial LLC bought a new position in shares of Maravai LifeSciences in the fourth quarter worth approximately $34,000. Insigneo Advisory Services LLC purchased a new stake in Maravai LifeSciences during the fourth quarter valued at approximately $34,000. Quantessence Capital LLC purchased a new stake in shares of Maravai LifeSciences in the third quarter valued at $31,000. Stifel Financial Corp bought a new stake in Maravai LifeSciences in the fourth quarter worth about $36,000. Finally, Jain Global LLC purchased a new position in Maravai LifeSciences during the 4th quarter valued at $36,000. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Price Performance

Shares of NASDAQ:MRVI traded up $0.12 during midday trading on Friday, hitting $6.09. The company’s stock had a trading volume of 4,388,991 shares, compared to its average volume of 2,776,341. The business’s 50 day simple moving average is $5.03 and its 200 day simple moving average is $3.94. The company has a debt-to-equity ratio of 0.72, a quick ratio of 4.96 and a current ratio of 5.91. The company has a market cap of $1.57 billion, a P/E ratio of -8.58 and a beta of 0.65. Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.99 and a 12-month high of $6.55.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.06. The company had revenue of $65.84 million during the quarter, compared to the consensus estimate of $53.00 million. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. On average, analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on MRVI shares. UBS Group reaffirmed a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Wall Street Zen raised Maravai LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday, May 8th. Finally, Wells Fargo & Company lifted their price objective on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a report on Friday, May 8th. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Maravai LifeSciences presently has a consensus rating of “Hold” and an average target price of $5.50.

Insider Buying and Selling

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total transaction of $126,500.00. Following the transaction, the general counsel owned 360,767 shares of the company’s stock, valued at approximately $1,825,481.02. The trade was a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.49% of the company’s stock.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.